An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
NCT07680166 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 182
Last updated 2026-08-31
Summary
A study of XTMAB-16 in patients with pulmonary sarcoidosis
Conditions
- Pulmonary Sarcoidosis
Interventions
- DRUG
-
XTMAB-16
Infusion
- DRUG
-
Infusion
Sponsors & Collaborators
-
Xentria, Inc.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-10-30
- Primary Completion
- 2029-10-31
- Completion
- 2029-10-31
- FDA Drug
- Yes
More Related Trials
-
An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
NCT00072592 ·Status: COMPLETED ·Phase: PHASE1
-
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
NCT00104299 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
NCT01613599 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
NCT01024036 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Different Doses of Rituximab Therapy in Pemphigus Patients
NCT07457944 ·Status: COMPLETED
-
Rituximab in Interstitial Pneumonitis
NCT02251964 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
NCT04871191 ·Status: RECRUITING ·Phase: PHASE3
-
BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis
NCT07151690 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)
NCT02725476 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab for Anti-cytokine Autoantibody-Associated Diseases
NCT01842386 ·Status: COMPLETED ·Phase: PHASE1
-
Exploratory Study on LNP-mRNA Drugs Targeting CD19/BCMA for the Treatment of Relapsed and Refractory Autoimmune Diseases
NCT07388212 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
NCT02169219 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants
NCT06797375 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
NCT07389499 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases
NCT02990286 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Tofacitinib in Treating ANCA-associated Vasculitis
NCT04973033 ·Status: COMPLETED ·Phase: NA
-
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis
NCT06933563 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
NCT07203404 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Rituximab in the Treatment of Patients With Bullous Pemphigoid
NCT00286325 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
NCT07233642 ·Status: RECRUITING ·Phase: PHASE1
-
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
NCT07161193 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
NCT07676266 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
NCT07305116 ·Status: RECRUITING ·Phase: PHASE1
-
Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
NCT07184450 ·Status: RECRUITING ·Phase: PHASE1
-
Repurposing Tilmanocept for Cardiac Sarcoidosis
NCT07159074 ·Status: RECRUITING ·Phase: PHASE2